Date post: | 09-Mar-2016 |
Category: |
Documents |
Upload: | strata-media-group |
View: | 227 times |
Download: | 4 times |
THE 3RD WORLD CONGRESS ON
CONTROVERSIES IN THEMANAGEMENT OF VIRAL HEPATITIS
C-HEP
ISTANBUL, 2013See you there!
THE 2ND WORLD CONGRESS ON
CONTROVERSIES IN THEMANAGEMENT OF VIRAL HEPATITIS
C-HEP
BERLiN, GERmaNy • OCTOBER 18-20, 2012
PROGRAM
www.comtecmed.com/chep • [email protected]
C-HEP cover RUN.indd 1 4/10/12 15:18:51
You are cordially invited to attend the satellite symposium at the 2nd World Congress on Controversies in the Management of Viral Hepatitis (C-Hep)
DAAs: Raising Standards in Patient Care
Chair: Thomas Berg, Germany
on Thursday 18 October 2012, 18:00–19:15Hall A, Leonardo Royal Hotel Berlin, Germany
Janssen Pharmaceutica NV
With the support of Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA EMEA/HEP/0812/0804
C-HEP Advert A4_Layout 1 13/09/2012 10:25 Page 1
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBERLIN, GERMANY • OCTOBER 18-20, 2012
C-HEP PARTICIPANTS CAME FROM…
37 Countries (as of October 2, 2012)
Azerbaijan Bahrain Belgium Canada Czech Republic
Denmark Estonia Finland France Georgia
Germany Greece Hungary India Israel
Italy Japan Lithuania Luxembourg Malta
Nigeria Norway Poland Portugal Qatar
Romania Russia Serbia Slovak Republic Spain
Sweden Switzerland Thailand Turkey UK
USA Vietnam
C-HEP cover RUN.indd 2 4/10/12 15:18:54
THE 2ND WORLD CONGRESS ON
CONTROVERSIES IN THEMANAGEMENT OF VIRAL HEPATITIS
C-HEP
BERLiN, GERmaNy • OCTOBER 18-20, 2012
PROGRAM
www.comtecmed.com/chep • [email protected]
You are cordially invited to attend the satellite symposium at the 2nd World Congress on Controversies in the Management of Viral Hepatitis (C-Hep)
DAAs: Raising Standards in Patient Care
Chair: Thomas Berg, Germany
on Thursday 18 October 2012, 18:00–19:15Hall A, Leonardo Royal Hotel Berlin, Germany
Janssen Pharmaceutica NV
With the support of Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA EMEA/HEP/0812/0804
C-HEP Advert A4_Layout 1 13/09/2012 10:25 Page 1
01-26-C-HEP-part 1.indd 3 4/10/12 15:07:43
01-26-C-HEP-part 1.indd 4 4/10/12 15:07:48
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 5 ]
TIMETABLE
SATuRDAy, OCTObER 20, 2012HaLL a
08:30-10:30 PLENARy SESSION 10 HBV therapy in 2012
10:30-11:00 Coffee Break
11:00-11:45 PLENARy SESSION 11 interactive Case Session and Discussion: The challenging hepatitis B Case Supported by an unrestricted grant from Gilead Sciences Europe Ltd.
11:45-12:45 PLENARy SESSION 12 HCV – Looking to the Future
12:45-13:00 Farewell Toast
THuRSDAy, OCTObER 18, 2012HaLL a
14:00-16:00 PLENARy SESSION 1 Hepatitis C – addressing the Challenge
16:00-17:30 PIPELINE SHOWCASE New Drugs on the Horizon
17:30-18:00 Coffee Break and Poster Exhibition
18:00-19:15 SATELLITE SyMPOSIuM JANSSEN PHARMACEuTICALS Daas: Raising standards in patient care
19:15-20:30 Welcome Reception Sponsored by Abbott
FRIDAy, OCTObER 19, 2012HaLL a HaLL B
09:00-11:00 PLENARy SESSION 2 HCV Direct acting antivirals: How have the treatment paradigms changed
11:00-11:30 Coffee Break
11:30-12:15 SESSION 3 SESSION 4 Do we need to know genetic factors such HCV therapy is for specialists only? as iL28B for treatment decision making?
12:15-13:00 Lunch
13:00-14:15 SATELLITE SyMPOSIuM MERCK SHARP & DOHME Successful HCV Treatment in the Real World: Lessons From Clinical Practice
14:15-15:45 PLENARy SESSION 5 Hepatitis: State of the art Clinical Care
15:45-16:15 Coffee Break and Poster Prize Ceremony
16:15-17:00 SESSION 6 SESSION 7 Should patients wait for Daa combination Resistance to HCV Protease inhibitors: therapy? Game over?
17:00-17:30 SESSION 8 SESSION 9 interactive Case Session: How to treat HCV interactive Case Session: How to treat HCV in relapse after Liver Transplant? HiV coinfection Supported by an unrestricted grant from Boehringer Ingelheim
01-26-C-HEP-part 1.indd 5 4/10/12 15:07:50
Value through Innovation
Boehringer Ingelheim Is Advancing
NEXT�GENERATION AGENTS
Aiming to Deliver Improved TreatmentsOur rigorous HCVersoTM clinical trial program is designed
to answer the difficult questions in HCV: how to reduce
the burden of treatment and cure more patients.
Ultimately, Eliminating the Need for InterferonWith interferon-free treatment regimens, we strive to reach our
goal of delivering a more convenient cure for patients.
The novel clinical investigational compounds may offer the
potential for new therapies with greater efficacy, improved
tolerability, and shorter treatment duration compared with
current approaches in HCV treatment.
If you would like to learn more about Boehringer Ingelheim, visit us at www.boehringer-ingelheim.com.
S:190 mmS:277 m
mT:210 mm
T:297 mm
B:216 mmB:303 m
m
01-26-C-HEP-part 1.indd 6 4/10/12 15:07:51
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 7 ]
TABLE OF CONTENTS
Welcome Note 9
Committees 10
Faculty 12
CmE accreditation 15
Sponsors 16
acknowledgements 17
Exhibition Floorplan 21
Partners 22
Endorsements 23
General information 24
Scientific Program 27
Thursday, October 18, 2012 29
Friday, October 19, 2012 31
Saturday, October 20, 2012 34
index 35
Value through Innovation
Boehringer Ingelheim Is Advancing
NEXT�GENERATION AGENTS
Aiming to Deliver Improved TreatmentsOur rigorous HCVersoTM clinical trial program is designed
to answer the difficult questions in HCV: how to reduce
the burden of treatment and cure more patients.
Ultimately, Eliminating the Need for InterferonWith interferon-free treatment regimens, we strive to reach our
goal of delivering a more convenient cure for patients.
The novel clinical investigational compounds may offer the
potential for new therapies with greater efficacy, improved
tolerability, and shorter treatment duration compared with
current approaches in HCV treatment.
If you would like to learn more about Boehringer Ingelheim, visit us at www.boehringer-ingelheim.com.
S:190 mm
S:277 mm
T:210 mm
T:297 mm
B:216 mm
B:303 mm
01-26-C-HEP-part 1.indd 7 4/10/12 15:08:01
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 8 ]
01-26-C-HEP-part 1.indd 8 4/10/12 15:08:09
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 9 ]
DEAR FRIENDSAND COLLEAGUES,
Following the success of the 1st World Congress on Controversies in the management of Viral Hepatitis (C-Hep), we are very pleased to have you here in Berlin to participate in the 2nd C-Hep Congress.
The large attendance and enthusiastic feedback of the 1st Congress held last may in Barcelona highlighted the need for such a meeting focusing on the needs of the busy clinician caring for HCV and HBV infected patients. The C-Hep Congress attempts to summarize all the key new data recently presented – and how it might be implemented in routine care of Hepatitis B and C patients. Overviews, state of the art lectures and controversial debates with the outstanding faculty of prominent world leaders presenting both pro and con positions challenge and explore the optimal treatment for patients, including the appropriate use of new drugs. This educational Congress focuses on clinical practices in Viral Hepatitis and benefits not only Hepatologists and infectious Diseases specialist, but also general practitioners, internists and primary care physicians with a desire to gain knowledge in these exciting advances.
The format includes a significant allocation of time for interactive debates and questions from the audience to each panel of experts. Participants are encouraged to take an active role in the discussions with faculty members which follow each debate, in a unique and open environment.
We look forward to having you participate during the 2nd C-Hep Congress in the lovely city of Berlin.
Sincerely, Jürgen Rockstroh mD Jonathan M. Schapiro mD Germany israel
Co-Chairpersons
01-26-C-HEP-part 1.indd 9 4/10/12 15:08:14
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 10 ]
Jürgen Rockstroh, mDGermany
Jonathan M. Schapiro, mDisrael
CO-ChAIRPERSONS
hCV PROGRAM DIRECTOR
Stefan Zeuzem, GermanyKlinikum der J.W. Goethe-Universitat, Med. Klinik 1
hBV PROGRAM DIRECTOR
Fabien Zoulim, FranceINSERM U1052, Lyon University, Hepatology Department, Hospices Civils de Lyon
01-26-C-HEP-part 1.indd 10 4/10/12 15:08:17
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 11 ]
SCIENTIFIC COMMITTEE
David back, UKDepartment of Molecular and Clinical Pharmacology, University of Liverpool
Thomas berg, GermanyHead of the Division of Hepatology, Department of Internal Medicine, Clinic of Gastroenterology and Rheumatology, University Hospital Leipzig
Raffaele bruno, italyDepartment of Infectious Diseases, Hepatology Outpatients Unit, University of Pavia Fondazione IRCCS, Policlinico San Matteo, Pavia
Maria buti, SpainHospital Valle Hebron, Barcelona
bonaventura Clotet, SpainHIV Unit and irsicaixa Foundation, University Hospital “Germans Trias i Pujol”, Badalona, Catalonia
Douglas T. Dieterich, USa Professor of Medicine, Mount Sinai School of Medicine, New York
Geoffrey Dusheiko, UKUCL Centre for Hepatology, University College London Medical School, and Royal Free Hospital, London
Rafael Esteban, SpainVall d’Hebron University Hospital
Michael P. Manns, Germany Hannover Medical School, Department of Gastroenterology, Hepatology and Endocrinology
Stefan Mauss, Germany Center for HIV and Hepatogastroenterology, Duesseldorf
Jean Michel Pawlotsky, France Department of Virology, Henri Mondor Hospital, University of Paris
Carlo Perno, italyTor Vergata University Hospital, Rome
Marion Peters, USa Chief of Hepatology Research, Division of Gastroenterology, University of California, San Francisco
Jörg Petersen, Germany Liver Unit, IFI Institute for Interdisciplinary Medicine, Asklepios Klinik St. Georg, Hamburg
Massimo Puoti, italyDepartment of Infectious Diseases. AO Ospedale Niguarda Ca’ Granda, Milan
Vicente Soriano, Spain Hospital Carlos III, Madrid
Mark R. Thursz, UK Professor of Hepatology, Imperial College, London
Hans L. Tillmann, USaDuke Clinical Research Institute
Heiner Wedemeyer, Germany Hannover Medical School
01-26-C-HEP-part 1.indd 11 4/10/12 15:08:26
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 12 ]
FACULTY
Matthew Albert, FranceImmunobiology of Dendritic Cells, Institut Pasteur, Paris
David back, UKDepartment of Molecular and Clinical Pharmacology, University of Liverpool
Thomas berg, GermanyHead of the Division of Hepatology, Department of Internal Medicine, Clinic of Gastroenterology and Rheumatology, University Hospital Leipzig
Michel biermer, GermanyHepatologie und Gastroenterologie, University Hospital Leipzig
Raffaele bruno, italyDepartment of Infectious Diseases, Hepatology Outpatients Unit, University of Pavia Fondazione IRCCS, Policlinico San Matteo, Pavia
Maria buti, SpainHospital Valle Hebron, Barcelona
Geoffrey Dusheiko, UKUCL Centre for Hepatology, University College London Medical School, and Royal Free Hospital, London
Rafael Esteban, SpainVall d’Hebron University Hospital
Graham Foster, UKProfessor of Hepatology, Queen Marys University of London
Christoph Hezode, FranceHôpital Henri-Mondor, Université Paris-Est Créteil
Patrick Ingiliz, GermanyMedical Center for Infectious Diseases, Berlin
Karine Lacombe, FranceInfectious and Tropical Diseases Department, Saint-Antoine Hospital (AP-HP) & INSERM, UMR-S707 Paris
Christian M. Lange, Germany Department of Internal Medicine 1, Johann Wolfgang Goethe University Hospital Frankfurt a. M.
Maud Lemoine, FranceINSERM, UMR-S707 & Hopital Saint-Antoine, Paris
Michael P. Manns, Germany Hannover Medical School, Department of Gastroenterology, Hepatology and Endocrinology
Stefan Mauss, Germany Center for HIV and Hepatogastroenterology, Duesseldorf
Marie-Louise Michel, France Pasteur Institut and Inserm U845, Paris
Mark Nelson, UKChelsea and Westminster Hospital, London
Claus Niederau, GermanyDirector of the Department of Medicine, Katholische Kliniken Oberhausen, St. Josef- and St. Marienhospital, Academic Teaching Hospital of the University of Duisburg-Essen
Jean Michel Pawlotsky, France Department of Virology, Henri Mondor Hospital, University of Paris
01-26-C-HEP-part 1.indd 12 4/10/12 15:08:39
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 13 ]
FACULTY
Marion Peters, USaChief of Hepatology Research, Division of Gastroenterology, University of California, San Francisco
Jörg Petersen, Germany Liver Unit, IFI Institute, Asklepios Klinik St. Georg, Hamburg
Stanislas Pol, FranceStanislas Pol, France Université Paris Descartes & Hôpital Cochin, Paris
Massimo Puoti, italyDepartment of Infectious Diseases. AO Ospedale Niguarda Ca’ Granda, Milan
Jürgen Rockstroh, GermanyDepartment of Medicine, University Hospital Bonn
Christoph Sarrazin, GermanyProfessor of Medicine, Department of Internal Medicine 1, J.W. Goethe-University Hospital, Frankfurt
Jonathan M. Schapiro, israel National Hemophilia Center, Sheba Medical Center
Eckart Schott, GermanyDepartment of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin
Vicente Soriano, Spain Hospital Carlos III, Madrid
ulrich Spengler, GermanyProfessor for Hepatotology, Department of Medicine, University Hospital Bonn
Mark R. Thursz, UK Professor of Hepatology, Imperial College, London
Florian van bömmel, GermanyDepartment of Hepatology and Gastroenterology, University Hospital Leipzig
Heiner Wedemeyer, Germany Hannover Medical School
Stefan Zeuzem, GermanyKlinikum der J.W. Goethe-Universitat, Med. Klinik 1
Fabien Zoulim, FranceINSERM U1052, Lyon University, Hepatology Department, Hospices Civils de Lyon
01-26-C-HEP-part 1.indd 13 4/10/12 15:08:52
01-26-C-HEP-part 1.indd 14 4/10/12 15:09:00
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 15 ]
CME ACCREDITATION
The 2nd World Congress on Controversies in the Management of Viral Hepatitis (C-Hep) is accredited by the European accreditation Council for Continuing medical Education (EaCCmE) to provide the following CmE activity for medical specialists. The EaCCmE is an institution of the European Union of medical Specialists (UEmS), www.uems.net.
The 2nd World Congress on Controversies in the Management of Viral Hepatitis (C-Hep) is designated for a maximum of (or ‘for up to’) 11 hours of European external CmE credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the European Union of medical Specialists and the american medical association, physicians may convert EaCCmE credits to an equivalent number of ama PRa Category 1 Credits™. information on the process to convert EaCCmE credit to ama credit can be found at www.ama-assn.org/go/internationalcme.
Live educational activities, occurring outside of Canada, recognized by the UEmS-EaCCmE for ECmEC credits are deemed to be accredited Group Learning activities (Section 1) as defined by the maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.
01-26-C-HEP-part 1.indd 15 4/10/12 15:09:04
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 16 ]
SPONSORS
PLATINuM
GOLD
SILVER
SPONSORS
The C-Hep Congress gratefully acknowledges the generous support of the Sponosrs
01-26-C-HEP-part 1.indd 16 4/10/12 15:09:05
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 17 ]
ACkNOwLEDGEMENTS
PLATINuM
Janssen Pharmaceutical Companies of Johnson & Johnson50-100 Holmers Farm Way, High Wycombe, HP12 4DP United KingdomContact: Sarah WalkerTel: +44 7876.217.895 Fax: +44 131.301.0054 Email: [email protected] Website: www.stop-hepatitis-c.info
Janssen Pharmaceutical Companies of Johnson & JohnsonJanssen is committed to improving the lives of people impacted by hepatitis C worldwide by establishing innovative treatment regimens that significantly improve patient outcomes. Our strong heritage in virology will help us to become a leader in hepatitis C through the development of products that redefine the standard of care. in 2011, we launched iNCiVO® (telaprevir), a protease inhibitor co-developed with Vertex Pharmaceuticals inc, for patients suffering from genotype 1 chronic HCV. Visit: www.stop-hepatitis-c.info
Today’s mSD is a global healthcare leader working to help the world be well. mSD is known as merck in the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information visit www.merck.com and connect with us on Twitter, Facebook and youTube.
Merck Sharp & Dohme (MSD)One merck DrivePO Box 100Whitehouse Station, New Jersey 08889
01-26-C-HEP-part 1.indd 17 4/10/12 15:09:07
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 18 ]
ACkNOwLEDGEMENTS
F. Hoffmann-La Roche LtdF. Hoffmann-La Roche aG, Pharmaceuticals Division, Bldg 74/3O.Z02.18, CH-4070 Basel, SwitzerlandContact: Gabriel SchnetzlerTel: +41 (0) 61.687.76.76Fax: +41 (0) 61.688.23.48Email: [email protected]: www.roche.com
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare, with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.in the treatment of hepatitis C, Roche’s PEGaSyS (peginterferon alfa-2a [40KD]) has proven efficacy supported by extensive clinical and real-world experience. Over the last decade PEGaSyS has been studied in 11 pivotal clinical trials involving over 5700 patients, and more than 2 million patients have now been treated globally.
GOLD
Gilead Sciences Ltd 2 Roundwood avenue, Stockley Park Uxbridge UB11 1aF United Kingdom
Gilead Sciences, a research-based biopharmaceutical company, discovers, develops and commercializes innovative medicines in areas of unmet need. Gilead’s focus includes liver disease, HiV/aiDS and serious cardiovascular and respiratory conditions. With each new discovery and experimental drug candidate, we seek to improve the care of patients suffering from life-threatening diseases. Founded in 1987 in Foster City, California, Gilead employs some 4,000 people worldwide. as Gilead grows, so do our responsibilities as a corporate citizen and since 2003 our HiV access program has provided antivirals at substantially reduced prices in low- and middle-income countries.
boehringer Ingelheim Binger Strasse 173 ingelheim, 55216Germany Contact: Dr Reinhard malinTel: (0) 6132.77.90815Fax: (0) 6132.77.6601Email: [email protected]: www.boehringer-ingelheim.com
Boehringer ingelheim is a research-driven pharmaceutical group of companies dedicated to serving humankind by researching, developing, manufacturing and marketing pharmaceuticals that improve health and quality of life. Virology is one of seven R&D areas with Hepatitis C at the centre of interest. Our dedicated HCV treatment development programme, HCVersoTm, aims to deliver improved HCV treatment outcomes for patients, breaking down the barriers of current regimens and pursue new interferon free treatment paradigm.as part of this program, Boehringer ingelheim has advanced the clinical investigation of the 2nd wave protease inhibitor faldaprevir, and the combination of faldaprevir with the polymerase inhibitor Bi 207127 in an interferon-free setting into Phase iii.
01-26-C-HEP-part 1.indd 18 4/10/12 15:09:08
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 19 ]
ACkNOwLEDGEMENTS
Abbott200 abbott Park Road06mi, aP34-3abbott Park 60064-6189Contact: Dirk van Eeden, director Public affairs, abbott internationalTel & Fax: +1 847.938.8848 Email: [email protected] Website: www.abbott.com
bristol-Myers Squibb GmbH & Co. KGaAContact: mr. Knut Hannibal-TeichmannTel: +49 89.12142.474Fax: +49 89.12142.464Email: [email protected]
abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries.
Bristol-myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. around the world, our medicines are helping millions of patients in their fight against such diseases as cancer, cardiovascular disease, diabetes, hepatitis b, HiV, psychiatric disorders, and rheumatoid arthritis. For more information, please visit www.bms.com.
SILVER
01-26-C-HEP-part 1.indd 19 4/10/12 15:09:09
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 20 ]
ACkNOwLEDGEMENTS
SPONSORS
Rottapharm | Madaus Colonia-allee 15 Koln, 51067 Germany Contact: Cristina LambertiTel: +39 (0) 39.73.901Fax: +39 (0) 39.73.90.372Email: [email protected]: www.rotta.com
The italian company Rottapharm|madaus has a significant worldwide franchise and expertise in several medical fields, including hepatology/gastroenterology, with leading products such as Legalon and Legalon-SiL (silymarin and silibinin, sold in most Countries as anti-toxic treatments for liver pathologies ranging from NaSH to acute mushroom poisoning).New R&D developments in the same area will further strengthen the company’s relationship with Hepatologists over the next few years. in particular, Silibinin has been granted the orphan drug designation from Ema and FDa for the prevention of recurrent hepatitis C in liver transplant recipients.
Idenix Pharmaceuticals, Inc.60 Hampshire StreetCambridge, ma 02139Contact: Kelly BarryTel: 617.995.9800Fax: 617.995.9801Email: [email protected] Website: www.idenix.com
Novartis Pharma AGForum 1, Novartis Campus, 4056 BaselContact: Christian C. RothTel: +41 (0) 61.324.3122Email: [email protected]: www.novartis.com
idenix Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Our current primary research and development focus is on the treatment of patients infected with the hepatitis C virus (HCV). We are headquartered in Cambridge, massachusetts. Our clinical development operations and drug discovery operations are conducted in Cambridge and the company’s European laboratory in montpellier, France.The chemists and biologists leading the idenix drug discovery team have substantial experience in the creation or modification of antiviral drugs. idenix is able to rapidly discover compounds amenable to robust development and manufacturing processes. Building on our expertise in nucleoside chemistry and other small molecule chemistry and biology, we believe idenix is well positioned to become a leader in antiviral pharmaceuticals.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. in 2011, the Group achieved net sales of USD 58.6 billion, while approximately USD 9.6 billion (USD 9.2 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 126,000 full-time-equivalent associates and operate in more than 140 countries around the world.
01-26-C-HEP-part 1.indd 20 4/10/12 15:09:11
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 21 ]
EXhIBITION FOORPLAN
MAINENTRANCE
POSTERS
REGISTRATION
EXHIbITION
2
63
HALL
A
HALL
b
COMPANY STAND
Bristol-myers Squibb 3
merck Sharp & Dohme (mSD) 2
Rottapharm | madaus 6
01-26-C-HEP-part 1.indd 21 4/10/12 15:09:16
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 22 ]
PARTNERS
EVENT PARTNERS
MEDIA PARTNERS
The american Conference for the Treatment of HiV (aCTHiV) may 10-12, 2012Denver, CO, USa
E-aHPBa congress December 12-13, 2012
UK, London
6th Conference of the Union Europe Region July 4-6, 2012
UK, London
Prague Hepatology meeting 2012 September 20-22, 2012Prague, Czech Republic
international Liver Cancer association (iLCa)September 14-16, 2012
Berlin, Germany
01-26-C-HEP-part 1.indd 22 4/10/12 15:09:19
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 23 ]
ENDORSEMENTS
01-26-C-HEP-part 1.indd 23 4/10/12 15:09:20
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 24 ]
GENERAL INFORMATION
CONGRESS VENUELeonardo Royal Hotel BerlinOtto-Braun-Strasse 90D-10249, Berlin, GermanyTel.: +49 (0) 30-755 430 0Fax: +49 (0) 30-755 430 810Email: [email protected]: www.leonardo-hotels.com/Royal_Berlin_Hotel
LANGUAGEEnglish is the official language of the Congress.
REGISTRATION AND hOSPITALITY DESkThe Registration Desk will operate during the following hours:
Thursday, October 18, 2012 11:00-20:00
Friday, October 19, 2012 08:00-17:30
Saturday, October 20, 2012 08:00-12:40
CONGRESS kIT AND NAME TAGName tags are included in your personal Congress Kit. Please wear your name tag during all sessions and social events.
Key colors for name tags:
CERTIFICATE OF ATTENDANCEyour Certificate of attendance is included in your personal Congress Kit.
C-hEP FEEDBACk FORMPlease note that you have a C-Hep-CmE Feedback Form in your Congress Kit. We would greatly appreciate hearing your comments. Once completed, this form may be handed in to the Registration Desk.
LIST OF PARTICIPANTSa list of pre-registered participants is displayed on the notice board. Please correct or add your name and address wherever necessary.
INTERNET AND EMAILFree internet and email facilities will be available during Congress hours.
REFREShMENTSCoffee and tea will be served during the coffee breaks between sessions, as specified in the Timetable.
LUNChESa buffet lunch will be served for participants of the Congress on Friday, October 19, 2012 12:15-13:00. Please present your name tag at the entrance.
2ND WORLD CONGRESS ON
CONTROVERSIES IN THEMANAGEMENT OF VIRAL HEPATITIS
C-HEP
BERLiN, GERmaNy • OCTOBER 18-20, 2012
blue: Participants
2ND WORLD CONGRESS ON
CONTROVERSIES IN THEMANAGEMENT OF VIRAL HEPATITIS
C-HEP
BERLiN, GERmaNy • OCTOBER 18-20, 2012
Orange: Faculty
01-26-C-HEP-part 1.indd 24 4/10/12 15:09:23
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 25 ]
GENERAL INFORMATION
SPEAkERS’ PREVIEw ROOMSpeakers are invited to visit the Speakers’ Preview Room prior to their lecture and upload their presentation(s). Speakers should bring their slide presentations to be uploaded for their sessions no later than one break prior to the session in which they are scheduled. The Speakers’ Preview Room will be open during Congress hours as follows:
Thursday, October 18, 2012 11:30-20:30
Friday, October 19, 2012 08:00-17:30
Saturday, October 20, 2012 07:30-12:40
POSTER PRESENTATIONPoster presenters should plan to be beside their posters during the designated coffee breaks, as specified in the program. Please see the Congress Secretariat for board allocation at the Congress. Posters should be mounted on Thursday, October 18, 2012 at 14:00-17:30 and removed by 12:45 on Saturday, October 20, 2012.The Organizing Committee is not responsible for posters that are not removed on time.Poster presentation times are as follows:
Thursday, October 18, 2012 17:30-20:30
Friday, October 19, 2012 09:00-17:30
Saturday, October 20, 2012 08:30-12:45
EXhIBITION hOURSThursday, October 18, 2012 14:00-20:30
Friday, October 19, 2012 10:30-17:30
Saturday, October 20, 2012 10:00-12:45
SAFETY AND SECURITYPlease do not leave your personal belongings, bags or suitcases unattended at anytime.
LIABILITYThe Congress Secretariat and Organizers cannot accept liability for personal accidents, nor loss of or damage to private property of participants, either during or directly arising from the 2nd World Congress on Controversies in the management of Viral Hepatitis (C-Hep). Participants should make their own arrange-ments with respect to health and travel insurance.
CONGRESS SECRETARIAT
01-26-C-HEP-part 1.indd 25 4/10/12 15:09:25
One liver. One life. One VIREAD.
First-line treatment for chronic hepatitis B (CHB) in adults with compensated liver disease and decompensated liver disease1
Reference: 1. VIREAD, Summary of Product Characteristics. January 2012.VIR/IHQ/12-09//1199 Date of preparation: September 2012
Viread® 245 mg film-coated tabletsActive substance: tenofovir disoproxil (as fumarate). Composition: Each Viread film-coated tablet contains 245 mg of tenofovir disoproxil (as fumarate). Excipients: core: croscarmellose sodium, lactose monohydrate, magnesium stearate (E572), microcrystalline cellulose (E460), pregelatinised starch (gluten free). Coating: glycerol triacetate (E1518), hypromellose (E464), indigo carmine aluminium lake (E132). lactose monohydrate, titanium dioxide (E171). Therapeutic indications: HIV-1 infection: in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults. Hepatitis B infection: for the treatment of chronic hepatitis B in adults with compensated liver disease (with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels
and histological evidence of active inflammation and/or fibrosis) or with decompensated liver disease. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Warning: contains lactose monohydrate. Undesirable effects: Very common (≥1/10): hypophosphatemia, dizziness, diarrhoea, vomiting, nausea, rash, asthenia. Common (≥1/100, <1/10): headache, abdominal pain, abdominal distension, flatulence, increased transaminases, fatigue. Uncommon (≥1/1,000, <1/100): hypokalemia, pancreatitis, rhabdomyolysis, muscular weakness, increased creatinine. Rare (≥1/10,000, <1/1,000): lactic acidosis, hepatic steatosis, hepatitis, angioedema, osteomalacia, myopathy, acute renal failure, renal failure, acute tubular necrosis, proximal
renal tubulopathy (including Fanconi syndrome), nephritis (including acute interstitial nephritis), nephrogenic diabetes insipidus. Other possible side effects: hypertriglyceridemia, hypercholesterolemia, insulin resistance, hyperglycemia, hyperlactataemia, lipodystrophy, immune reactivation syndrome, osteonecrosis, hepatomegaly. Pharmaceutical form and pack sizes: Packs containing 30 and 3 x 30 film-coated tablets. Medicinal product subject to medical prescription. Information as of: January 2012. Marketing authorisation holder: GILEAD Sciences International Ltd., Cambridge, CB21 6GT, UK. Representative in Germany: Gilead Sciences GmbH, 82152 Martinsried b. Munich.
Maximising outcomes
GIVI0041_Hep-C-Advert_AW.indd 1 18/09/2012 11:5301-26-C-HEP-part 1.indd 26 4/10/12 15:09:28
THE 2ND WORLD CONGRESS ON
CONTROVERSIES IN THEMANAGEMENT OF VIRAL HEPATITIS
C-HEP
BERLiN, GERmaNy • OCTOBER 18-20, 2012
SCIENTIFIC PROGRAM
www.comtecmed.com/chep • [email protected]
27-34-C-HEP-part 2.indd 1 4/10/12 14:58:21
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 28 ]
NOTES
27-34-C-HEP-part 2.indd 2 4/10/12 14:58:22
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 29 ]
14:00-16:00 PLENARY SESSION 1 HEPATITIS C – ADDRESSING THE CHALLENGE moderators: Jürgen Rockstroh, Germany; Jonathan M. Schapiro, Israel
14:00-14:05 Chairpersons Conference Welcome address
14:05-14:30 HCV in 2020: any cases left? Rafael Esteban, Spain14:30-14:35 Discussion
14:35-15:00 HCV vaccine: where do we stand? Ulrich Spengler, Germany15:00-15:05 Discussion
interferon-free HCV therapy: are we getting there?15:05-15:25 No: Graham Foster, UK15:25-15:45 yes: Heiner Wedemeyer, Germany15:45-16:00 Discussion
16:00-17:30 PIPELINE ShOwCASE NEW DRUGS ON THE HORIzON moderator: Jonathan M. Schapiro, Israel
16:00-16:05 introduction
16:05-16:20 Strategies towards cure of HCV infection: a personalized approach Heiner Wedemeyer, Germany Presentation supported by BMS
16:20-16:35 Combination Daa Therapy for Hepatitis C Douglas Mayers, USA Presentation supported by Idenix
16:35-16:50 Host targeting therapies for the treatment of Hepatitis C Claudio Avila, Switzerland Presentation supported by Novartis
16:50-17:05 The aNNaPURNa study: Evaluating the Combination of Setrobuvir, Danoprevir/r and Ribavirin With or Without mericitabine in Patients With Chronic Hepatitis C Eckart Schott, Germany Presentation Supported by Roche
17:05-17:20 Silibinin dihydrogensuccinate for the prevention of hepatitis C recurrence after liver transplantation and treatment of non-responders to anti-HCV therapy Lucio Rovati, Italy Presentation Supported by Rottapharm | Madaus
17:20-17:30 Panel Discussion
17:30-18:00 Coffee Break and Poster Exhibition
SCIENTIFIC PROGRAM
[ HALL A ]
THURSDAy, OCTObER 18, 2012
27-34-C-HEP-part 2.indd 3 4/10/12 14:58:23
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 30 ]
18:00-19:15 SATELLITE SYMPOSIuM JANSSEN PhARMACEuTICALS DAAs: RISING STANDARDS IN PATIENT CARE
18:00-18:05 Welcome and introduction: Thomas berg, Germany18:05-18:25 Practical recommendations in the era of Daas: Vlad Ratziu, France18:25-18:45 managing Daa treatment in HiV-HCV co-infected patients: Massimo Puoti, Italy18:45-19:05 Understanding our patients: challenging clinical cases: Marina berenguer, Spain19:05-19:15 Summary and key learnings: Thomas berg, Germany
19:15-20:30 wELCOME RECEPTION Sponsored by Abbott
SCIENTIFIC PROGRAM
[ HALL A ]
THURSDAy, OCTObER 18, 2012
27-34-C-HEP-part 2.indd 4 4/10/12 14:58:24
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 31 ]
09:00-11:00 PLENARY SESSION 2 HCV DIRECT ACTING ANTIVIRALS: HOW HAVE THE TREATMENT PARADIGMS CHANGED moderators: Stefan zeuzem, Germany; Eckart Schott, Germany
09:00-09:05 Overview of HCV sessions by HCV Program Director: Stefan zeuzem, Germany
Direct antivirals: how have the treatment paradigms changed?09:05-09:10 moderators introduction
HCV Direct acting antivirals:09:10-09:30 in treatment naïve: Stanislas Pol, France09:30-09:50 in treatment experienced: Thomas berg, Germany09:50-10:10 Toxicity management: Christoph Hezode, France10:10-10:40 Drug-drug interactions: David back, UK10:40-11:00 Panel discussion
11:00-11:30 Coffee Break
11:30-12:15 SESSION 3 (parallel session) DO WE NEED TO kNOW GENETIC FACTORS SUCH AS IL28b FOR TREATMENT DECISION MAkING?
11:30-11:45 yes: Vincent Soriano, Spain11:45-12:00 No: Mathew Albert, France12:00-12:15 Discussion
11:30-12:15 SESSION 4 (parallel session) HCV THERAPy IS FOR SPECIALISTS ONLy?
11:30-11:45 yes: Marion Peters, USA11:45-12:00 No: Michael biermer, Germany12:00-12:15 Discussion
12:15-13:00 Lunch
SCIENTIFIC PROGRAM
[ HALL A ]
[ HALL b ]
FRIDAy, OCTObER 19, 2012
27-34-C-HEP-part 2.indd 5 4/10/12 14:58:26
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 32 ]
[ HALL b ]
13:00-14:15 SATELLITE SYMPOSIuM MERCK ShARP & DOhME SUCCESSFUL HCV TREATMENT IN THE REAL WORLD: LESSONS FROM CLINICAL PRACTICE Chairperson: Jürgen Rockstroh, Germany
13:00-13:05 Welcome and Opening Remarks: Jürgen Rockstroh, Germany13:05-13:20 Emerging Evidence Guiding Clinical Practice: Christoph Sarrazin, Germany13:20-13:40 Optimizing Outcomes with Protease inhibitors: adverse Events management and Prevention of Resistance: Jean Michel Pawlotsky, France13:40-14:00 Protease inhibitors in Practice: Case Studies: Geoffrey Dusheiko, UK14:00-14:10 Panel Discussion14:10-14:15 Closing Remarks: Jürgen Rockstroh, Germany
14:15-15:45 PLENARY SESSION 5 HEPATITIS: STATE OF THE ART CLINICAL CARE
14:15-14:35 Fatty liver disease: what do we know? Claus Niederau, Germany14:35-14:55 Vitamin D and liver disease: Which role does it play? Christian M. Lange, Germany14:55-15:15 End-stage liver disease: What is new? Marion Peters, USA15:15-15:35 Treatment of HCC: state of the art: Massimo Puoti, Italy17:35-17:45 Panel Discussion
15:45-16:15 Coffee Break and Poster Prize Ceremony
16:15-17:00 SESSION 6 (parallel session) SHOULD PATIENTS WAIT FOR DAA COMbINATION THERAPy?
16:15-16:30 yes: Patrick Ingiliz, Germany 16:30-16:45 No: Geoffrey Dusheiko, UK16:45-17:00 Discussion
16:15-17:00 SESSION 7 (parallel session) RESISTANCE TO HCV PROTEASE INHIbITORS: GAME OVER?
16:15-16:30 yes: Jean Michel Pawlotsky, France16:30-16:45 No: Christoph Sarrazin, Germany16:45-17:00 Discussion
SCIENTIFIC PROGRAM
[ HALL A ]
FRIDAy, OCTObER 19, 2012
27-34-C-HEP-part 2.indd 6 4/10/12 14:58:27
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 33 ]
17:00-17:30 SESSION 8 (parallel session) HOW TO TREAT HCV RELAPSE AFTER LIVER TRANSPLANT? iNTERaCTiVE CaSE SESSiON
Case discussion: How to treat HCV relapse after OLTX Raffaele bruno, Italy
17:00-17:30 SESSION 9 (parallel session) HOW TO TREAT HCV IN HIV CO-INFECTION iNTERaCTiVE CaSE SESSiON Supported by an unrestricted grant from Boehringer Ingelheim
Case discussion: How to treat HCV in HiV coinfection Stefan Mauss, Germany
SCIENTIFIC PROGRAM
[ HALL A ]
[ HALL b ]
FRIDAy, OCTObER 19, 2012
27-34-C-HEP-part 2.indd 7 4/10/12 14:58:28
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012
[ 34 ]
08:30-10:30 PLENARY SESSION 10 HbV THERAPy IN 2012 moderators: Fabien zoulim, France; Jörg Petersen, Germany
08:30-08:35 Overview of HBV sessions by HBV Program Director: Fabien zoulim, France
08:35-09:00 Hepatitis B Therapy: State of the art and open challenges: Jörg Petersen, Germany
is there a need for combination therapy? 09:00-09:15 yes: Florian van bömmel, Germany09:15-09:30 No: Maria buti, Spain
09:30-09:50 HBV preventive and therapeutic vaccines: what is new? Marie-Louise Michel, France
09:50-10:10 Hepatitis Delta: What is new? Heiner Wedemeyer, Germany
10:10-10:30 Panel discussion
10:30-11:00 Coffee Break
11:00-11:45 PLENARY SESSION 11 THE CHALLENGING HEPATITIS b CASE iNTERaCTiVE CaSE SESSiON aND DiSCUSSiON moderator: Fabien zoulim, France Supported by an unrestricted grant from Gilead Sciences Europe Ltd.
Case discussion: The challenging hepatitis B case Mark Nelson, UK karine Lacombe, France
11:45-12:45 PLENARY SESSION 12 HCV – LOOkING TO THE FUTURE
11:45-12:05 Strategies to prevent HCC: what can we do? Mark Thursz, UK
12:05-12:20 Can we afford HCV Daas for all? Maud Lemoine, France
12:20-12:45 What are the remaining challenges in hepatitis research? Michael Manns, Germany
12:45-13:00 FAREwELL TOAST
SCIENTIFIC PROGRAM
[ HALL A ]
SATURDAy, OCTObER 20, 2012
27-34-C-HEP-part 2.indd 8 4/10/12 14:58:29
THE 2ND WORLD CONGRESS ON
CONTROVERSIES IN THEMANAGEMENT OF VIRAL HEPATITIS
C-HEP
BERLiN, GERmaNy • OCTOBER 18-20, 2012
INDEX
www.comtecmed.com/chep • [email protected]
The academy for Clinical Debates & Controversies in medicine announces
35-36-C-HEP-index.indd 1 4/10/12 15:01:52
Committed to Science that Matters
HCV
Copyright © 2012 Abbott. All rights reserved.
35-36-C-HEP-index.indd 2 4/10/12 15:01:54
1
Name Program Page
A
Albert, Matthew 31
Avila, Claudio 29
B
Back, David 31
Berenguer, Marina 30
Berg, Thomas 30, 31
Biermer, Michael 31
Bruno, Raffaele 33
Buti, Maria 34
D
Dusheiko, Geoffrey 32
E
Esteban, Rafael 29
F
Foster, Graham 29
H
Hezode, Christoph 31
I
Ingiliz, Patrick 32
L
Lacombe, Karine 34
Lange, Christian M. 32
Lemoine, Maud 34
Name Program Page
M
Manns, Michael P. 34
Mauss, Stefan 33
Mayers, Douglas 29
Michel, Marie-Louise 34
N
Nelson, Mark 34
Niederau, Claus 32
P
Pawlotsky, Jean Michael 32
Peters, Marion 31, 32
Petersen, Jörg 34
Pol, Stanislas 31
Puoti, Massimo 30, 31, 32
R
Ratziu, Vlad 30
Rockstroh, Jürgen 29, 32
Rovati, Lucio 29
S
Sarrazin, Christoph 32
Schapiro, Jonathan M. 29
Schott, Eckart 29, 31
Soriano, Vicente 31
Spengler, Ulrich 29
T
Thursz, Mark R. 34
2
Name Program Page
V
van Bömmel, Florian 34
W
Wedemeyer, Heiner 29, 34
Z
Zeuzem, Stefan 31
Zoulim, Fabien 34
You are cordially invited to attend the satellite symposium at the 2nd World Congress on Controversies in the Management of Viral Hepatitis (C-Hep)
DAAs: Raising Standards in Patient Care
Chair: Thomas Berg, Germany
on Thursday 18 October 2012, 18:00–19:15Hall A, Leonardo Royal Hotel Berlin, Germany
Janssen Pharmaceutica NV
With the support of Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA EMEA/HEP/0812/0804
C-HEP Advert A4_Layout 1 13/09/2012 10:25 Page 1
THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBERLIN, GERMANY • OCTOBER 18-20, 2012
C-HEP PARTICIPANTS CAME FROM…
37 Countries (as of October 2, 2012)
Azerbaijan Bahrain Belgium Canada Czech Republic
Denmark Estonia Finland France Georgia
Germany Greece Hungary India Israel
Italy Japan Lithuania Luxembourg Malta
Nigeria Norway Poland Portugal Qatar
Romania Russia Serbia Slovak Republic Spain
Sweden Switzerland Thailand Turkey UK
USA Vietnam
C-HEP cover RUN.indd 2 4/10/12 15:18:54
THE 3RD WORLD CONGRESS ON
CONTROVERSIES IN THEMANAGEMENT OF VIRAL HEPATITIS
C-HEP
ISTANBUL, 2013See you there!
THE 2ND WORLD CONGRESS ON
CONTROVERSIES IN THEMANAGEMENT OF VIRAL HEPATITIS
C-HEP
BERLiN, GERmaNy • OCTOBER 18-20, 2012
PROGRAM
www.comtecmed.com/chep • [email protected]
C-HEP cover RUN.indd 1 4/10/12 15:18:51